
\beginsupplement

# Supplement

|  **Condition**         | mFcγRI  |mFcγRIIB|mFcγRIII| mFcγRIV |Effectiveness|
| ---------------------- |--------:|-------:|-------:|--------:|------------:|
| **mIgG1**              |        0| 3000000|  300000|        0|         0.00|
| **mIgG2a**             |100000000|  400000|  700000| 30000000|         0.95|
| **mIgG2b**             |   100000| 2000000|  600000| 20000000|         0.20|
| **mIgG3**              | 20000000|       0|       0|        0|         0.00|
| **mIgG1-FcγRIIB-/-**   |        0|       0|  300000|        0|         0.70|
| **mIgG2a-FcγRIIB-/-**  |100000000|       0|  700000| 30000000|         1.00|
| **mIgG2b-FcγRIIB-/-**  |   100000|       0|  600000| 20000000|         0.75|
| **mIgG3-FcγRIIB-/-**   | 20000000|       0|       0|        0|         0.00|
| **mIgG2a-FcγRI-/-**    |        0|  400000|  700000| 30000000|         0.80|
| **mIgG2a-FcγRIII-/-**  |100000000|  400000|       0| 30000000|         0.93|
| **mIgG2a-FcγRI,IV-/-** |        0|  400000|  700000|        0|         0.35|
| **mIgG2b-Fucose-/-**   |   100000|10000000| 1100000|200000000|         0.70|

**Murine knockout conditions and mFcγR-mIgG affinities.** Murine knockout conditions and mFcγR-mIgG affinities used in principal component analysis shown in [@Fig:InVivoResults]. Values in columns labeled with mFcγRs are affinities with M\textsuperscript{-1} units [@Gavin20; @Guilliams:2014cm]. Values in the effectiveness column represent proportional reduction in lung metastases observed with treatment [@Nimmerjahn:2005hu].


| **Antigen** | **Isotype** | **Clone** | **Provider** |
| ----------- | ----------- | --------- | ------------ |
| **CD11b**   | rat IgG2b   | M1/70     | AbD Serotec; BioLegend |
| **CD45**    | rat IgG2b   | 30-F11    | BD Biosciences, BioLegend |
| **CD62L**   | rat IgG2a   | MEL-14    | eBioscience, BioLegend |
| **Gr-1 (Ly6G/C)** | rat IgG2b | RB6-8C5 | BD Biosciences, BioLegend |
| **Ly6G**    | rat IgG2a   | 1A8       | BD Biosciences, BioLegend |
| **NK1.1**   | mouse IgG2a | PK136     | Southern Biotech; Biolegend |
| **FcγR1 (CD64)** | mouse IgG1 | X54-5/7.1 | BD Biosciences |
| **FcγR2b (CD32b)** | mouse IgG2a | Ly17.2 | In-house |
| **FcγR3 (CD16)** | rat IgG2a | 275003 | R&amp;D Systems Europe |
| **FcγR4**   | Arm. hamster | 9E9      | In-house; Biolegend |

**Antibodies for cell identification and mFcγR quantitation.**


![**Parameter autocorrelation for each parameter and each walker.** Solid and dotted lines indicate the 95th and 99th percentile significance bounds.](./Figures/FigureAA.svg){#fig:Autocorrel}

![**Supplementary results to *in vivo* predictions.** A) Receptor abundance quantified across different peripheral immune cell populations. Error bars indicate standard error of biological replicates (N >= 3). B) Prediction performance upon crossvalidation for the model predicting *in vivo* efficacy with differing assumed IC concentration and avidity.](./Figures/FigureS2.svg){#fig:SuppTwo}
